The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Right to attend and registration

Those who wish to participate in the meeting must:

• be listed as a shareholder in the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 19 May 2026,
• give notice of intent to participate no later than 21 May 2026. Notification shall be made either in writing to Moll Wendén Advokatbyrå, Qlife AGM, Stortorget 8, 211 34 Malmö, or by email to QlifeAGM@mollwenden.se.

The notice should include the full name, personal identification number or corporate registration number, shareholding, address, daytime telephone number and, where applicable, information about representatives, proxies and assistants. The number of assistants may not be more than two (2). The notification should, where applicable, be accompanied by proxies, registration certificates and other documents of authority.

In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation in the annual general meeting, register its shares in its own name at Euroclear Sweden AB so that the shareholder is listed in the share register as of the record date of 19 May 2026. Such re-registration may be temporary (so-called voting rights registration), and a request for such voting rights registration shall be made to the nominee, in accordance with the nominee's routines, at such time in advance as decided by the nominee. Voting rights registration that has been made by the nominee no later than the second banking day after 19 May 2026 will be taken into account in the presentation of the share register.

Proxies, etc.

If a shareholder is to be represented by a proxy, the proxy must bring a written, dated and shareholder-signed proxy form to the general meeting. The proxy form must not be more than one (1) year old, unless a longer period of validity (but not exceeding five (5) years) is stated in the proxy form. If the proxy has been issued by a legal entity, the current registration certificate or equivalent authorisation document for the legal entity must also be provided. To facilitate the proceedings, a copy of the proxy and other documents of authority should be enclosed with the registration for the general meeting. Proxy forms will be available at the company's head office and on the company's website (www.qlifeholding.com), and will be sent by post to shareholders who contact the company and provide their address.

Proposed agenda

1. Opening of the meeting.
2. Election of the chairman of the meeting.
3. Preparation and approval of the voting list.
4. Approval of the agenda.
5. Election of one or two persons to verify the minutes.
6. Determination of whether the meeting has been duly convened.
7. Presentation of the annual report and audit report, as well as the consolidated accounts and the auditor's report on the consolidated accounts.
8. Address by the CEO.
9. Resolutions regarding:

1. the adoption of the income statement and the balance sheet and the consolidated income statement and consolidated balance sheet;
2. distribution of the company's result in accordance with the adopted balance sheet; and
3. discharge from liability for the members of the board and the CEO.

1. Determination of the number of board members, auditors and deputy auditors.
2. Determination of remuneration for the board of directors and auditor.
3. Election of the board of directors and auditor.
4. Resolution on authorising the board of directors to resolve on issue of shares, warrants and/or convertibles.
5. Closing of the meeting.

Proposed resolutions

Item 2: Election of the chairman of the meeting

Shareholders propose that attorney-at-law Henric Stråth, Moll Wendén Advokatbyrå, or, in his absence, the person appointed by the board of directors, is elected as chairman of the meeting.

Item 9 (b): Resolution on the distribution of the company's profit or loss in accordance with the adopted balance sheet

The board of directors has proposed to the 2026 annual general meeting that no dividend is paid and that the funds at the disposal of the general meeting are carried forward.

Item 10: Determination of the number of board members, auditors and deputy auditors

Shareholders propose that five (5) ordinary board members be appointed for the period until the end of the next annual general meeting. Shareholders further propose that one (1) registered audit firm, without a deputy, be appointed as auditor.

Item 11: Determination of remuneration for the board of directors and auditor

Shareholders propose that, for the period until the end of the next annual general meeting, remuneration to the board of directors shall be paid out with SEK 75,000 to the chairman of the board and SEK 75,000 to each of the other board members who are not employed by the company.

Shareholders propose that the remuneration to the auditor is to be paid in accordance with customary standards and an approved invoice.

Item 12: Election of the board of directors and auditor

Shareholders proposes re-election of Flemming Pedersen, Lars Staal Wegner, Mikael Persson, Jørgen Drejer and Jacob Glenting as board members and re-election of Flemming Pedersen as chairman of the board.

Information regarding the board members proposed for re-election is available on the company's website (www.qlifeholding.com).

Shareholders also proposes re-election of the registered auditing firm Göteborgs Revision Kommanditbolag as the company's auditor for the period until the end of the next annual general meeting. Göteborgs Revision Kommanditbolag has announced that authorised public accountant Mattias Olofson will continue to serve as the auditor-in-charge.

Item 13: Resolution on authorising the board of directors to resolve on the issue of shares, warrants and/or convertibles

The board of directors proposes that the general meeting authorise the board of directors to, on one or more occasions, during the period up to the next annual general meeting, with or without preferential rights for shareholders, resolve on new issues of shares, issues of convertible bonds and/or warrants. The issue resolution may be made against cash payment and/or with provisions regarding contribution in kind or set-off, or subscription may be permitted on other terms. The company's share capital and number of shares may, by virtue of the authorisation, be increased by an amount and number that does not exceed the limits set out in the articles of association in force at any given time or as adopted by the general meeting.

The board of directors, the CEO, or the person appointed by the board of directors or the CEO, shall be authorised to make any minor amendments required to register the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB, or due to other formal requirements.

For a valid resolution on the proposal in this item, the proposal has to be supported by shareholders representing at least two-thirds (2/3) of the votes cast as well as shares represented at the meeting.

Information at the meeting 

Shareholders present at the annual general meeting have the right to request information in accordance with Chapter 7, Section 32 of the Companies Act (2005:551).

Available documents

The complete proposals for resolutions and other documents that shall be made available prior to the meeting pursuant to the Swedish Companies Act will be made available at the company and at the company's website, www.qlifeholding.com, at least three weeks prior to the meeting. The documents will also be sent free of charge to shareholders who so request and provide their address to the company. In other respects, the board of directors' complete proposals for resolutions are stated in the notice.

Shares and votes in the company

The total number of shares and votes in the company amount to 28,874,177 as per the date of this notice. The company does not hold any own shares.

Processing of personal data

For information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

__________

Gothenburg, April 2026

Qlife Holding AB

The Board of Directors

For further information, please contact: 

Thomas Warthoe
Chief Executive Officer (CEO)
Phone: +45 21 63 35 34
Email: tw@egoo.health

About Qlife

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.